Jun 10 |
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
|
Jun 10 |
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
|
Jun 8 |
Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030
|
Jun 8 |
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
|
Jun 8 |
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
|
Jun 7 |
Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap
|
Jun 7 |
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
|
Jun 7 |
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
|
Jun 7 |
Is Eli Lilly and Company (LLY) A Good “Quality Stock” to Buy Now?
|
Jun 6 |
Can GLP-1 weight-loss drug manufacturers keep momentum up?
|